Landos Biopharma, Inc. (LABP)
| Market Cap | 414.74M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -30.14M |
| Shares Out | 39.16M |
| EPS (ttm) | -0.77 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | April 19 |
| Last Price | $10.59 |
| Previous Close | $11.51 |
| Change ($) | -0.92 |
| Change (%) | -7.99% |
| Day's Open | 11.50 |
| Day's Range | 10.45 - 11.50 |
| Day's Volume | 20,376 |
| 52-Week Range | 8.82 - 16.99 |
BLACKSBURG, Va., April 13, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with...
The FDA has signed off Landos Biopharma's (NASDAQ: LABP) Investigational New Drug application for omilancor (BT-11) for the treatment of Eosinophilic Esophagitis (EoE). Landos expects to initiate patien...
Third potential indication for omilancor (BT-11), a first-in-class candidate for the treatment of autoimmune diseases Third potential indication for omilancor (BT-11), a first-in-class candidate for the...
NX-13 was well tolerated with no reported serious adverse events
BLACKSBURG, Va., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma (Nasdaq: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with ...
BLACKSBURG, Va., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune dise...
Xontogeny’s Landos Biopharma is jumping into warm biotech IPO waters as it looks to go public with a $100 million offering.
On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.
Landos Biopharma, a Phase 2 biotech developing oral small molecule therapies for autoimmune diseases, filed on Wednesday with the SEC to raise up to $100 million in an initial public offering.
Landos Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.
About LABP
Landos Biopharma is a clinical-stage biopharmaceutical company developing novel, disease-specific oral therapeutic candidates designed to address the therapeutic gap in the current treatment paradigm for autoimmune diseases.. We believe the therapeutics we discover and develop, if approved, will have a significant impact on the quality of life of patients suffering from autoimmune diseases. While great strides have been made, existing approaches continue to leave patient needs unmet, due in part to significant safety concerns. Our core experti... [Read more...]
| Industry Biotechnology | IPO Date Feb 4, 2021 |
| CEO Josep Bassaganya-Riera | Employees 33 |
| Stock Exchange NASDAQ | Ticker Symbol LABP |